| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ... The lancet oncology 10 (3), 223-232, 2009 | 3030 | 2009 |
| Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial N Kalakonda, M Maerevoet, F Cavallo, G Follows, A Goy, JSP Vermaat, ... The Lancet Haematology 7 (7), e511-e522, 2020 | 289 | 2020 |
| Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study LE Budde, LH Sehn, M Matasar, SJ Schuster, S Assouline, P Giri, ... The Lancet Oncology 23 (8), 1055-1065, 2022 | 239 | 2022 |
| Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study J García-Suárez, J de la Cruz, Á Cedillo, P Llamas, R Duarte, ... Journal of hematology & oncology 13, 1-12, 2020 | 235 | 2020 |
| Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry J Lopez-Sendon, C Alvarez-Ortega, P Zamora Auñon, A Buño Soto, ... European heart journal 41 (18), 1720-1729, 2020 | 233 | 2020 |
| Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety W Hiddemann, AM Barbui, MA Canales, PK Cannell, GP Collins, J Dürig, ... Journal of Clinical Oncology 36 (23), 2395-2404, 2018 | 231 | 2018 |
| R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study A Martín, E Conde, M Arnan, MA Canales, G Deben, JM Sancho, ... Haematologica 93 (12), 1829-1836, 2008 | 212 | 2008 |
| Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol I Alvarez, A Sureda, MD Caballero, A Urbano-Ispizua, JM Ribera, ... Biology of Blood and Marrow Transplantation 12 (2), 172-183, 2006 | 190 | 2006 |
| Nutritional recommendations in hematopoietic stem cell transplantation M Martin-Salces, R de Paz, MA Canales, A Mesejo, F Hernandez-Navarro Nutrition 24 (7-8), 769-775, 2008 | 157 | 2008 |
| Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease E González Barca, E Domingo Domenech, FJ Capote, J Gómez Codina, ... Haematologica, 2007, vol. 92, num. 11, p. 1489-1494, 2007 | 151 | 2007 |
| Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte … KS Peggs, A Sureda, W Qian, D Caballero, A Hunter, A Urbano‐Ispizua, ... British Journal of Haematology 139 (1), 70-80, 2007 | 133 | 2007 |
| Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ... The Lancet Oncology 19 (11), 1530-1542, 2018 | 127 | 2018 |
| Long‐term follow‐up in patients treated with Mini‐BEAM as salvage therapy for relapsed or refractory Hodgkin's disease A Martin, MC Fernandez‐Jimenez, MD Caballero, MA Canales, ... British journal of haematology 113 (1), 161-171, 2001 | 121 | 2001 |
| Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) R Garcia-Sanz, A Sureda, F de la Cruz, M Canales, AP Gonzalez, ... Annals of Oncology 30 (4), 612-620, 2019 | 117 | 2019 |
| Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the … A Salar, E Domingo‐Domenech, C Estany, MA Canales, F Gallardo, ... Cancer 115 (22), 5210-5217, 2009 | 105 | 2009 |
| First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a … A Salar, E Domingo-Domenech, C Panizo, C Nicolás, J Bargay, ... The Lancet Haematology 1 (3), e104-e111, 2014 | 88 | 2014 |
| Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma A Salar, E Domingo-Domenech, C Panizo, C Nicolás, J Bargay, ... Blood, The Journal of the American Society of Hematology 130 (15), 1772-1774, 2017 | 85 | 2017 |
| Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab‐based regimens treatment? MJ Garcia‐Rodriguez, MA Canales, D Hernandez‐Maraver, ... American journal of hematology 83 (8), 673-675, 2008 | 70 | 2008 |
| A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma B Sanchez-Espiridion, C Montalban, A Lopez, J Menarguez, P Sabin, ... Blood, The Journal of the American Society of Hematology 116 (8), e12-e17, 2010 | 69 | 2010 |
| Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency Villar, Morado, Canales, Hernández, Sanjurjo, Quintana Haemophilia 6 (5), 588-590, 2000 | 68 | 2000 |
EVA DOMINGOHematologa Institut Catala d'Oncologia在 iconcologia.net 的电子邮件经过验证
